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Résumé 
Objectif: · . .,, 
Evaluer un remplacement de valve mitrale hors-pompe avec des stents 
valvés 
M.éthode: 
Des homografts préservés daps du glutaraldëhyde ont été sütur.és dans· 
une-prothèse tubulq.ite avarit d'êtr:e soudés à deux stents Z en nitinol potir 
creer d@ux couronnes auto- extensibles. A) Nous avons testé la valve in vitro 
en utilisant un circüit pülsatile fermé (mock loop) avant de débuter le.9 
expérienpes sur les porcs (n=8, 46.0± 4.3 kg: B). L'oreillette. gauche a été 
exposée pat thoracotomie g~:uohe et un ëh.emin auric:ulo-ventricülaire a été · 
. tracé par· ultrason intravasculaire (IVUS) et intrac-ardiaque (Navigate). ainsi 
que par fluôroscopie.· Les ste:tlts à double couroillle ont été comprimés 
radialement; puis insérés hors-pompe dans un système de déploiement 
développé dans notre laboratoire avant.d'être nüâchés en deux temps (stent 
ventriculaire avant stent aüriculaire ). 
Résultats: 
A) Les stents ont résisté aux tests \n vitro démontrant une stabilité de 
fonction et de fixation face à des pressions allant jusqu'à 120 mm Hg. B) 
Une évaluation in vivo a permis de qéterminer le diamètre de l'anneau mitral 
( 24;9±0.6mm) ainsi que la surface moyenne de la valve (421.4±17.Smm 2). 
La hauteur moyenne dès stents était égale à 29.4±0.2mm avec un diamè~re 
interne de 20.4±1.0mm et un diamètre externe de 25.5±0.8mm, Les stents 
implantés ont bien fonctionné tout au long de l'expérience. Le temps moyen 
de survie était de 97 .5±56.3 minutes (le temps de survie étant fixé entre 40 et 
180 minutes, nous sacrifii_ons le porc si celui-ci survivait au delà de cette 
limite). Une échocardiographîe . bidimensionnelle et un ultrason 
intravasculaire ont conflrmé \lll processus cl' ouverture et de fermeture de 
. valve intégral. Une évalu~tion. post-mortem a confirmé le positionnement 
c_ortect des stents valvés dans l.a position mitrale·. 
Conch1sioils: 
L'implantàtion ]}.ors pompe d'üp stent valvé auto-extensfüle est possible 
mais une performance à plus long terme doit encore être déterminée. 
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Introduction 
Since the heart-lung machine was successfully introduced in 1954[1] 
and the first Starr-Edwards valve was successfully implanted in a patient in 
1960[2], mitral valve replacement has generally been accomplished by using 
a cardiac surgical procedure with extracorporeal bypass. However, off-pump 
mitral valve replacement may provide an alternative for patients with mitral 
valve diseases, especially for those with severe heart failure as well as 
hepatic and renal function failure, where coagulation status is a big problem. 
A number of minimally invasive techniques for mitral valve repair or 
replacement have been developed recently. Video assisted and robotic mitral 
valve surgery was reported by Chitwood WR Jr in 2000[3], while, in 2003, 
endovascular edge-to-edge mitral valve repair was revealed by Frederick [ 4] 
and Peter performed a percutaneous mitral valve repair[ 5]. 
Nevertheless, off-pump mitral valve replacement has not been 
explored so far. 
We thought that it was possible to perform off-pump mitral valve 
replacement with a valved stent, although the idea of valved stent was not an 
original one. In 1965, Davies H. deployed a catheter-mounted unicuspid 
valve above the aortic valve for the relief of aortic insufficiency[ 6]. In 1971, 
Moulpoulos S. et al designed a catheter-mounted aortic valve that consists of 
an umbrella shaped membrane with a controlling unit that unfolds the 
valve[7]. In 1990, Andersen H.R. performed a transluminal implantation of a 
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new expandable artificial cardiac valve( the stent-valve) in the aorta and in 
the beating heart in a closed chest in pigs[8] and in 1992, he made a similar 
report[9]. The same year, Dusan Pavcnik performed transcatheter placement 
of a self-expanding caged-ball valve in the aortic valve position in 
dogs[lO]. In 1996, Moazami N. et al constructed a trileaflet stent valve with 
bovine pericardium sewn on the stent[ll] and in October of that same year, 
Robert C. et al developed a mock circulatory loop system to test valves in 
vitro[12]. In 2000, Sochman J. et al designed a catheter-based aortic valve 
consisting of a stent cage and a prosthetic flexible tilting valve dise [ 15]. 
Later that year, Bonhoeffer P. and Boudjemline Y. sutured a biological valve 
into a platinum stent and successfully performed a percutaneous pulmonary 
valve implantation in sheep[13]. Two years later, they designed a special 
valved stent to avoid blocking the coronary ostium and performed a 
percutaneous aortic valve replacement[l4]. In 2002, Lutter G. et al 
deployed a valved stent with barbs in a porcine aorta[16]. In 2003, Antonio F. 
Corno et al implanted the self-explanding valved stent in the vena cava[l 7], 
while that same year, Jun Qing Zhou et al achieved the successful 
implantation of a valved stent in the pulmonary position[18]. Then, in 2004, 
Christoph Buber explored whether valved stents compromised coronary 
flow.[19] 
All these experiments pioneered the use of valved stents but for the 
mitral valve, however, their implantation is brand-new. 
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Therefore, we designed a type of valved stent specially for 
atrio-ventricular valve and explored the feasibility of deployment in mitral 
position by trans-atrium approach using left thoracotomy without 
extracorporeal bypass. 
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1. History review 
1.1 Mitral valve repair 
Though the discussion about mitral valve surgery first arose at the 
tum of the last century, no one was to broach the subject seriously until the 
1920s, when a number of actual operations were undertaken. In 1923, Eliott 
Cutler performed the first transventricular mitral valvulotomy at the Peter 
Bent Brigham Hospital in Boston[20]. In 1925, Henry Souttar performed the 
first finger dilation of a mitral valve stenosis by transatrial approach[21]. 
Nevertheless, the number of failed cases was high enough to 
discourage the continuation of these operations, & another two decades 
elapsed before surgery on the mitral valve became a reality. It was only in 
1948 that Harken and Bailey performed their first transatrial 
commissurotomies, Bailey on the 1 oth June and Harken on the 16th June 
1948[22]. 
The advances of techniques in open-heart surgery were critical to the 
advances of mitral valve surgery. On 6 May 1953, John Gibbon performed 
the first successful open-heart operation on a human patient using a 
heart-lung machine[l], which was to play a pivota} role in providing 
surgeons the time and opportunity to look directly inside the heart. More 
extensive surgeries were henceforth developed. 
Lillehei completed the first surgical correction of mitral valve 
insufficiency in 1956[23]. Soon thereafter, surgical repair of both regurgitant 
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and stenotic mitral valves became common[24] and man y innovative reports 
conceming clinical experiences with annuloplasty appeared in the literature 
of the late 1950s and the following years[25]. Barnard, Carpentier, Duran, 
Kay, Lillehei, Kirklin among others narrowed the annulus in various ways, 
mostly by plicating sutures positioned in one or more places & rings of a 
number of designs and materials came into use. From the start, annuloplasty 
was generally used alone, and later, was accompanied by other valvular 
reparative manipulations. One of these methods consisted in placing a baffle 
adjacent to the faulty leaflet. Lillehei, for example, used rolled tubes and 
balls of Ivalon while in 1961, Barnard and his Cape Town colleagues 
described their mobile silastic baffle and dumbbell-shaped Ivalon 
subvalvular designs. On the other hand, Henry Nichols lengthened short 
leaflets by inserting a piece of plastic in a defect created by a periannular 
incision. Other methods involved using autogenous pericardium for leaflets' 
advancement, or to attach pliable plastic or biologie materials to the free 
edge. 
Alain Carpentier devised tnlly evolutionary- reconstn1ctive procedures 
for various heart valves. His techniques gradually gained a foothold in many 
clinics, were used with increasing satisfaction, and avoided valve excision 
and replacement in many instances[25]. 
But the development of successful prosthetic valves muted the 
interest in valve repair in 1960s. Mitral valve repair was infrequently used 
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because it was technically challenging and was overshadowed by the use of 
mechanical valves[24]. Sorne surgeons, however, continued to refine and 
expand the surgical techniques for repair of stenosis and regurgitation. 
Carpentier's group in France[26] and Duran's group in Spain[27] were the 
first major contributors. Carpentier, who not only introduced several repair 
techniques but also provided a functional classification of mitral valve 
lesions and their indicated surgical repair methods, first demonstrated the 
cnlCial fact that a quadrilateral resection of the diseased portions of the 
minor leaflet of the mitral valve could be safely performed with a minor 
leaflet excision as great as 2 to 4 cm. He also demonstrated that the thin 
mitral leaflet tissue could be removed and successfully sutured without 
dehiscence of the suture line in the reconstructed leaflets when cardiac 
contractions began and generated systolic pressures ranged from 1 OO to 120 
mmHg[28]. Carpentier primarily performed a careful annuloplasty, 
supported by a prosthetic ring, which removed tension from the suture line 
in the leaflets. Furthermore, the shortening of elongated chordae to the 
anterior leaflet and the technique of chordal transposition were developed by 
him in 1983[29]. 
Within the last two decades, mitral valve repair operations increased 
dramatically in number[30]for the following reasons. First of all, mitral 
valve replacement is associated with long-term complications, such as 
bleeding, embolism etc., thus surgeons prefer to undertake mitral valve 
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repair instead. Second of all, surgeons have gradually improved techniques 
for valve repair and have increased their understanding of functional defects 
of the mitral valve and associated components. As a consequence, mitral 
valve repair has become the preferred method for nearly all mitral valvular 
diseases, which include degenerative valve disease, ruptured chordae, mitral 
valve prolapse, myxomatous valves, and some cases of rheumatic valve 
disease[3 l]. 
Nowadays, surgeons mainly use mitral repair procedures devised by 
Carpentier, which include patching of leaflet perforations, shortening of 
chordae to restore normal valve coaptation, transpositioning or replacing 
chordae to improve leaflet coaptation, and prevention of further dilation and 
maintainance of normal annular diameter with the insertion of annuloplasty 
rings[32]. Recently, relatively straightforward mitral repairs have been 
performed by video-assisted[33] or minimally invasive techniques[34][35], 
percutaneous endovascular edge-to-edge repair[4][5], and robotic mitral 
valve repair with the da Vinci Surgical Systemand[3]. All these methods 
may have great promise in the field of cardiovascular surgery. 
9 
1.2 Mitral valve replacement 
The first reported mitral valve replacement took place on 22 July 
1955 in England, with Judson Chesterman performing the surgery. The 
patient survived for 14 hours[36]. 
As the heart-lung machine was successfully introduced in 1954, 
dreams of replacing diseased heart valves with prosthetic devices initiated 
the great "valve rush" of the late 1950s and early l 960s. Numerous 
investigators were involved in attempts to use tissues, plastics, Teflon, 
silicone rubbers, polyurethane, Dacron and metals as substitutes for leaflets 
or whole valves. However, there were many problems as the valves tended 
to wear and tear and sometimes broke. Thrombosis was also a common 
problem[25]. 
The first Starr-Edwards valve was implanted successfully in a patient 
on August 25, 1960, marked a tuming point in cardiac valve surgery[2]. It 
had a solid silastic ball and a cage of methyl methacrylate attached to the 
Teflon-cloth-covered stainless steel sewing ring, which was easy to insert. It 
soon gained widespread usage. 
In order to reduce the protn1sion of the prosthesis into the left 
ventricle when it was placed in the mitral position, valves with a lower 
profile were developed. A number of tilting dise valves were produced in the 
late 1960s and during the next decade. The Bjork-Shiley tilting dise 
prostheses, m which the cage was Stellite and the final dise pyrolytic 
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carbon-coated graphite, became the most widely used prosthesis at the 
time[37][38]. In the late 1970s, the St. Jude valve, with its light-weight, 
very low profile, hinged, pyrolytic carbon, bi-leaflet, was one of the most 
extensively used valves and remains popular still today[39]. Similar 
effective dise prostheses in current use include the Medtronic-Hall, 
Omniscience, Carbomedics amongst others[ 40]. However, the unsolved 
problem of thromboembolism with metallic prostheses led to the 
investigation of tissue prostheses [ 41]. 
In 1962, the use of homografts in the aortic position was described by 
Ross[ 42]. But for the mitral position, it was troublesome to manage the 
chordae tendineae. Because of the problems of inserting homografts in the 
mitral area, Clarence Weldon at Hopkins published laboratory experiences 
with the use of aortic homografts mounted on a frame, which greatly 
facilitated their placement in animals[25]. In 2000, A.Sampath reported that 
37 patients underwent mitral valve replacement with homografts, but the 
au th ors didn 't achieve the desired results [ 4 3]. 
In 1967, Ross successfully perfornied replacement of aortic and mitral 
valves with a pulmonary autograft [ 44]. Another promising type of autograft 
was used in Zurich by Ake Senning in 1975[45]. He mounted the fascia lata 
upon a frame with a sewing ring to replace the aortic valve, but their value 
as mitral valve substitutes was considered controversial. 
Heterografts were first used by Carpentier in 1965[46], and in 1968 
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Carpentier and Dubost reported experiences with heterograft replacement of 
mitral and tricuspid valves[25]. In 1969, Kaiser and Hancock were the first 
to report the implantation of a porcine aortic valve fixed with glutaraldehyde, 
and this valve later evolved into the Hancock porcine xenograft[47]. In 1971, 
Carpentier first used the term bioprosthesis for heterografts[ 48]. Five years 
later, the Carpentier-Edwards bioprosthesis was introduced, which differed 
from the Hancock bioprosthesis by being mounted on a flexible support 
frame, instead of a rigid one[23]. Both the Carpentier-Edwards and Hancock 
bioprostheses[ 49] have been used successfully in the mitral position and 
continue to be used, even to this day. 
However, both the mechanical and the bioprosthetic valves have their 
shortcomings. It was recognized that the major clinical problems with 
mechanical valves was thromboembolism and that bioprostheses had limited 
durability because of valve degeneration[50]. People are trying to find a 
"perfect" valve, and maybe, bioengineered prosthetic heart valves represent 
a new and promising strategy that is just now beginning to unfold[ 41]. 
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1.3 The valved stent 
In 1965, Davies H. deployed a catheter-mounted unicuspid valve 
above the aortic valve for the relief of aortic insufficiency[6]. In 1971, 
Moulpoulos S. et al designed a catheter-mounted aortic valve that consists of 
an umbrella shaped membrane with a controlling unit that unfolds the 
valve[?]. In 1990, Andersen H.R. performed the transluminal implantation 
of a new expandable artificial cardiac valve( the stent-valve) in the aorta and 
the beating heart of closed chest in pigs[8]. Then, in 1992, he had a same 
report[9]. The same year, Dusan Pavcnik performed the transcatheter 
placement of a self-expanding caged-ball valve in the aortic valve position 
in dogs[lO]. In 1996, Moazami N. et al constructed a trileaflet stent valve 
with bovine pericardium sewn on the stent[ll] and in October of that year, 
Robert C. et al developed a mock circulatory loop system to test valves in 
vitro[l2]. In 2000, Bonhoeffer P. and Boudjemline Y. sutured a biological 
valve into a platinum stent and successfully performed a percutaneous 
pulmonary valve implantation in sheep[l3]. Two years later, they designed a 
special valved stent to avoid blocking the coronary ostium and performed 
percutaneous aortic valve replacement[14]. Back in 2000, Sochman J. et al 
designed a catheter-based aortic valve consisting of a stent cage and a 
prosthetic flexible tilting valve disc[15]. In 2002, Lutter G. et al deployed a 
valved stent with barbs in a porcine aorta[16]. Then, in 2003, Antonio 
F.Como et al implanted the self-explanding valved stent in the vena cava[l 7] 
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and the same year, Jun Qing Zhou et al managed to implante a valved stent 
in the pulmonary position[l8]. Most recently, in 2004, Christoph Huber 
undertook the experiment: Do valved stents compromise coronary flow?[19] 
Valved stents for the mitral valve were not reported so far. 
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2. Anatomy of mitral valve 
2.1 Components of mitral valve: 
A thorough understanding of mitral valve anatomy and its 
relationship to other cardiac stn1ctures is required for successful mitral valve 
surgery. The mitral valve is a complex structure made up of several subunits 
that work in conjunction to produce mitral valve competence. These 
components include the annulus, anterior and posterior leaflets, chordae 
tendineae & the anterolateral and posteromedial papillary muscles[ 51]. 
The annulus is asymmetrical, with a fixed portion ( corresponding to 
the anterior leaflet) shared with the aortic annulus and a dynamic portion 
( corresponding to the posterior leaflet) that represents most of the 
circumference of the annulus. The fibrous mitral annulus is a dynamic 
structure whose circumference changes from diastole to systole. The annulus 
is D-shaped, with the straight portion representing the area of continuity 
between the mitral and aortic valves. This continuity is limited by the right 
and left fibrous trigones. It remains constant during the cardiac cycle and is 
rarely distorted by valvular disease. 
The two leaflets are asymmetrical as the anterior leaflet has the 
greater length of tissue but occupies a smaller portion of the circumference 
of the annulus than the posterior. The anterior leaflet is twice the height of 
the posterior leaflet but has half its annular length (Fig 1). Both mitral 
leaflets are normally similar in area. The larger (anterior) leaflet is roughly 
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triangular in shape, with the base of the triangle inserted at about one-third 
of the annulus. It partially separates the ventricular inflow and outflow 
tracts (Fig 2, video 1 in CD-rom). The anterier leaflet has a relatively smooth 
free margin with few or no indentations. There is a distinct ridge separating 
the region of closure (rough zone) from the remaining leaflet ( clear zone). 
The clear zone is devoid of direct chordal insertions. The posterior mitral 
leaflet is rectangular and is usually divided into three scallops with the 
middle scallop being the largest of the three in the majority of normal hearts. 
The smaller (posterior) leaflet inserts into about two-thirds of the annulus 
and has rough and clear zones corresponding to those of the anterior leaflet, 
as well as a basal zone close to the annulus, which receives chordae directly 
from left ventricular trabeculae[52]. 
The chordae join each papillary muscle to the corresponding 
commissure and the adjoining halves of both leaflets and maintain the two 
leaflets in a position allowing coaptation. The tendinous cords are string-like 
structures that attach the ventricular surface or the free edge of the leaflets to 
the papillary muscles. The normal mitral leaflets have no chordal insertions 
into the ventricular septum, unlike the tricuspid valve which has chordal 
attachments to the ventricular septum allowing it to be distinguished from 
the mitral valve on cross-sectional echocardiography. The tendinous cords of 
the mitral valve are attached to two groups of papillary muscles or directly 
to the postero-inferior ventricular wall to form the tensor apparatus of the 
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valve. Cords that arise from the apices of the papillary muscles attach to 
both leaflets of the mitral valve. Since cords usually branch distal to their 
muscular origins, there are five times as many cords attached to the leaflets 
as there are to the papillary muscles. 
The two papillary muscles and the adjacent wall attach the mitral 
apparatus to the left ventricle. Viewed from the atrial aspect, the two groups 
are located beneath the commissures, occupying anterolateral and 
posteromedial positions(Fig 3). As a functional unit, the papillary muscle 
includes a portion of the adjacent left ventricle wall. Papillary muscle 
contraction pulls the two leaflets toward one another and thereby promotes 
valve closure[53]. 
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Fig 1. Mitral valve, viewed from left atrial aspect 
Anterior leaflet 
Fig 2. The anterier leaflet partially separates the ventricular inflow and 
outflow tracts (Endoscopie View) 
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papillary muscle 
(PMPM) 
Fig 3. Gross anatomy of the mitral valve and papillary muscle-chordal 
apparatus, as demonstrated in an excised and unfolded valve 
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2.2 Special anatomy: 
The septal (anterior) leaflet is in fibrous continuity with the aortic 
valve through the aortic-mitral annulus and forms one of the boundaries of 
the left ventricular outflow tract. This region of continuity occupies about 
one-quarter of the mitral annulus and corresponds to the region beneath half 
of the left coronary cusp and half of the noncoronary cusp of the aortic 
valve . The limits of this attachment are demarcated by the right and left 
fibrous trigones. These points do not correspond to the commissures of the 
mitral valve. The AV node and bundle are at risk of surgical damage adjacent 
to the right trigone[54]. 
Anatomically important structures during mitral valve surgery also 
include the left circumflex coronary artery, which courses within the left 
atrioventricular groove near the anterolateral commissure, and the coronary 
sinus, which courses within the left atrioventricular groove adjacent to the 
annulus of the posterior mitral leaflet (Fig 4 ). 
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Right trigone 
(conduction 
fiber region) 
Fig 4. Gross anatomy of the mitral valve and adjacent structures 
2 l 
3. In vitro evaluation of valved stents 
3.1 Device construction 
The following steps describe the procedure followed in constructing 
valved stents. 
(1) A glutaraldehyde preserved aortic or pulmonary valvular homograft 
was trimmed to only keep the three leaflets and commissures (Fig 5 A).The 
diameter of the homografts was 20.46±1.0lmm (Tab 1). 
(2) A length of Dacron prosthesis was eut to fit the height of 
commissure of homograft (Fig 5 B). The diameter of the Dacron prosthesis 
was 23.80±1.09mm, and its height was 15.42±0.77mm (Tab 1). 
(3) The aortic or pulmonary valvular homograft was mounted into the 
Dacron segment with a running suture of 6-0 prolene. It was important to 
keep the natural shape of the homograft (Fig 5 C). 
( 4) Two self-expandable Z nitinol stents were dismantled from an 
endovascular stent graft (Talent) (Fig 5 D). The diameter of the stents was 
30mm, while their height was 15mm (Tab 1). 
(5) Two self expandable Z stents were sutured at the center of the 
mounted Dacron segment with 6-0 prolene, avoiding distortion of the 
valvular homograft. It was the custom-made valved stent which looks like 
double crowns (Fig 5 E). The dimension of 5 valved stents was measured 
(Tab 2). 
(6) All the valved stents were preserved in the glutaraldehyde solution. 
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Fig 5. The valved stent and each ofits parts. 
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3.2 Valved stent delivery system construction 
The delivery system consists of one guide wire sheath, an interior 
piston and an exterior Teflon sheath (30F), as shown in Fig 6. They were eut 
clown to 25-30 cm in length, which was easier to manipulate. The introducer 
tip couldn't be too long, because there was not enough space in left ventricle. 
The valved stent was compressed to a small size and mounted inside the 
Teflon sheath. Before being released by withdrawing the outside catheter 
while holding the inside piston in place. After deployment, the introducing 
system was withdrawn. The delivery process in vitro is shown in video 2. 
Video 2. Valved stent delivery process in vitro 
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Fig 6. Valved stent delivery system 
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3.3 Device leakage test 
3.3.1 Objective: 
To test regurgitation of valved stents under static water pressure. 
3.3.2 Materials: 
• 5 Glutaraldehyde preserved valved stents 
• One Dacron vessel prosthesis with an inner diameter of26mm 
• A water reservoir 
• A connecting tube 
• A clamp 
• A container and a measuring cylinder 
• Aruler with 1500 mm 
• An electronic timer 
3.3.3 Methods: 
The valved stented was tested for leakage by subjecting it to a pressure 
of 80cm of water (or 60mmHg) . It was then sutured into a Dacron prosthesis 
tube ( <P 26mm) at its center by a running suture and connected to the water 
column (Fig 7) . Leakage from the valved stent was confirmed by measuring 
the rate of water leakage below it. The rate of water filtered through the 
Dacron prosthesis was subtracted from the rate of water leaked through the 
Dacron prosthesis/stent in order to calculate the net leakage rate of valved 
stent. 
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Fig 7. Static leakage test 
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3.3.4 Results: 
In vitro static performance testing of the 5 valved stents showed a mean 
leakage rate of 41.5±10.1 ml/min when subjected to a simulated afterload of 
60mmHg, (See Tab 3). 
3.3.5 Conclusion: 
The new valved stent has little regurgitation under a static pressure of 
60mmHg. 
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3.4 Mock loop simulation test 
3.4.1 Objective: 
To test the valved stents in an in vitro simulated dynamic circulation 
system. 
3.4.2 Materials 
• A pig's heart 
• 5 custom-made valved stents 
• A self-made valved stent delivery system. 
• A pulsatile pump (Datascope System 83). 
• Several connecting tubes 
• 2 reservoirs 
• 3 5F Millar pressure transducer catheters (mpc-500, Houston, Texas, 
USA.) 
• A data recording system (Sampling rate 50 Hz) 
• An intravascular ultrasound (Clearview, Boston Scientific 
Corporation, Sunnyvale, Califomia) 
• An intra-cardiac ultrasound, ICUS (Navigate, Accuson) 
• An endoscope (Karl-Storz). 
3.4.3 Methods 
3.4.3.1 Setup of the Mock loop 
To simulate the characteristics of the normal left heart system, a 
mock circulatory loop system was set up according to Fig 8. The 
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picture of this experiment is shown in Fig 9. The testing process in vitro 
is shown in video 3. 
Before the test, the aorta , left atrium & apex of heart were sewn 
with a Dacron tube prosthesis ( cP 25mm), which can facilitate a 
connection with the silicone tube (Fig 10). 
The system was powered by a ventricular-assist device (Datascope 
System 83). The pneumatic pump was pulsatile and the pulse rate and 
pressure in our system could be regulated easily. 
3 0 
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Fig 8. Schematic mock loop. 1, Pulsatile ventricular-assist device. 
2, Left ventricle. 3, Left atrium. 4, Valved stent. 5, Aorta. 6, Right 
atrium. 7, Connective silicone tube. 8, Water reservoir A (90cm in 
height). 9, Water reservoir B (20cm m height). 10, Endoscope. 
11, Intravascular ultrasound (IVUS). 12, Computer and pressure 
recording system. 13 , Intra-cardiac ultrasound (ICUS). 14, Flow 
recording system. 15, Machine pump (Datascope System 83) 
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Fig 9. Mock loop device and the dynamic test of the valve 
Fig 10. The aorta,left atrium & apex of heart were sewn 
with a Dacron prosthesis 
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3.4.3.2 Deployment of the valved stent 
Using an endoscope, the valved stent was deployed into the mitral 
annulus of heart via a Dacron tube sewn to left atrium. The valved stent 
delivery process is explained in paragraph 3.2 
3.4.3.3 Measurement 
The Millar catheter was used to measure the pressure in the aorta, left 
atrium and left ventricle. 
The Intravascular ultrasound (IVUS) catheter was inserted through the 
hemostatic valve to the valved stent to measure valvular function. 
The endoscope was used to show intracardiac structures on video. 
3.4.4 Results 
( 1) During the experiment, pressures of LV and LA both before & after 
implantation were measured(see Fig 11). The diastolic gradient across the 
valved stent (mitral position) was almost zero space (0.48mmHg) at a mean 
flow rate of 2.81±0.26 L/Min. There was no difference between before and 
after implantation. 
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Fig 11. The pressure curves recorded by computer. 
LV 1: left ventricle pressure before implantation; 
LV2: left ventricle pressure after implantation; 
LA 1: left atrium pressure before implantation; 
LA2: left atrium pressure after implantation; 
(2) Intra-vascular ultrasound showed complete valve closure and 
opening. The open area of the valved stent was 254.8±10.5mm2 and the open 
diameter was 19.6±1.4 mm (Fig 12, video 4 in CD-rom). 
Fig 12. IVUS views of the valved stent in Mock loop test 
3 4 
(3) Endoscope imaging showed complete valve closure and opening 
(Fig 13)(Video 5 in CD-rom). The valve was well fixed in the mitral annulus 
without any migration. 
Fig 13. Endoscope imaging showing complete 
valve closure of valved stent 
3.4.5 Conclusion: 
The competence of the valved stent tested favorably under our mock 
loop system according to the IVUS, endoscope and Millér catheter findings. ,..., 
The valved stent was secured appropriately in the mitral valve position. 
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4. In vivo evaluation of valved stents 
Background: 
Valved stents have been studied for 40 years. The first attempt was 
reported in 1965, when H. Davies deployed a catheter-mounted unicuspid 
valve above the aortic valve for the relief of aortic insufficiency[6]. Years 
later, some innovative reports conceming animal experiments or clinical 
experiences with valved stent appeared in the literature, performed by 
Moulpoulos S.[7], Andersen H.R.[8], Dusan Pavcnik[lO], Moazami N.[11], 
Bonhoeffer P., Boudjemline Y.[13,14], Lutter G.[16] & von Segesser 
L.K.[17-19]. Several expandable valved stents were designed and off-pump 
or percutaneous transcatheter implantations of valved stent were performed, 
including positioning in the aorta, aortic valve, pulmonary valve & verra 
cava. Unfortunately, valved stents for mitral valve were not reported as of 
yet. 
The mitral valve is generally considered to be the one of most 
important cardiac valves. Mitral valve repair and replacement is commonly 
achieved using extracorporeal bypass. If, however, replacement could be 
accomplished with an off-pump, it would be valuable endeavour. 
This experiniental study has been designed to evaluate the feasibility of 
an off-bypass implantation of a self-expandable valved stent in the mitral 
position. 
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4.1 Materials: 
Materials used were as follows: 
• 5 custom-made valved stents. 
• 2.5% Isoflurane for general anaesthesia. 
• Heparin. 
• A self-made valved stent delivery system. 
• An X-ray machine (Telam C cornet) 
• An intravascular ultrasound, IVUS (Clearview, Boston Scientific 
Corporation, Sunnyvale, Califomia). 
• An intra-cardiac ultrasound, ICUS (Navigate, Accuson) 
• A machine for anaesthesia ( Drager sulla 909v). 
• An oximeter (Ohmeda4700). 
• An ECG and Pressure recording system (HEWLETT PACKARD 
Madel 88s). 
4.2 Methods: 
4.2.1 Valved stent and its'delivery system preparation 
The valved stents were constructed as described in Chapter 3 .1. After 
the leakage and mock loop tests, these stents were sterilized and stored in 
glutaraldehyde solution. 
The valved stent was compressed to a small size and mounted inside a 
Teflon sheath in order for open-end of the valve to face the introducer tip, as 
described in Chapter 3.2. 
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4.2.2 Preparation of animais 
8 pigs weighing 46.0±4.3kg ( 43-56kg), received care in compliance 
with the "Principles of Laboratory Animals" formulated by the National 
Society of Medical Research and «the Guide for the Care and Use of 
Laboratory Animals» prepared by the Institute of Laboratory Animal 
Resources and published by the National Institute of Health (NIH 
publication 85-23, revised 1985). The protocol was approved by the 
Institutional Committee on Animal Research. The pigs' data is seen m 
Table 4. 
After undergoing general anaesthesia with tracheal intubation and 
mechanical ventilation (ketamine 22mg/kg and atropine 0.8mg/kg 
intramuscularly, Thiopental 15mg/kg intravenously for induction, Isoflurane 
2.5% for maintenance anesthesia), the pigs' left carotid artery was exposed 
and a catheter was introduced to monitor the blood pressure. Likewise, both 
the left and right internai jugular veins were exposed for infusion and 
introduction of a Swan-Ganz catheter respectively. The left femoral vein was 
also exposed for insertion of an intracardiac ultrasonic probe (Fig 14). 
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Fig 14. Preparation of the experiment 
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4.2.3 Implantation strategy 
Under the continuous monitoring of an electrocardiogram measuring, 
the arterial pressure, central venous pressure and oxygen saturation, we 
made a left posterolateral thoracotomy in the fourth intercostal space and 
opened the pericardium to reach the left atrium. The mitral valve diameter, 
area and flow were measured by two-dimensional ultrasonography (the 
probe was directly put on the surface of left atrium) .( Fig 15). 
Fig 15. Left posterolateral thoracotomy 
We marked the atrio-ventricular groove with 3-4 clips, showing the 
position of mitral annulus, thus regarding it as the valved stent implantation 
site . 
Heparin (1 OOIU/kg) was administered intravenously. An intracardiac 
ultrasonic probe was inse1ied into right atrium through the left femoral vein 
in order to monitor our intracardiac manipulations. 
Two purse strings were made with 6-0 prolene on the left atrium, a 
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needle then punctured it, a guide wire was inserted & a short 9-F sheath was 
introduced. 
The intravascular ultrasound (IVUS) Catheter (6F, 12.5MHZ 
transducer) was inserted, the diameter and area of mitral valve were 
measured and the position of annulus was confirmed under the guidance of 
fluoroscopy. 
An incision of 1 cm was made on left atrium, controlled by the purse 
strings. The custom-made delivery introducer loaded with the valved stent 
was pushed along the guide wire, until the stent was located at the desired 
site ( the center of stent overlapped with clips under fluoroscopy). The 
sheath was pulled back while the piston was held in place, and the first half 
of the valved stent was deployed. We gently pulled the whole introducer to 
ensure fixation of the valved stent before deploying the second half (Fig 16). 
ECG, BP, HR, Sa02, CO, PAP, WPAP, CVP were monitored every 15 
minutes. 
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Fig 16. Delivery of the valved stent under the guidance of fluoroscopy 
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4.2.4 Measurement 
The intracardiac ultrasound (ICUS), intravascular ultrasound (IVUS) 
and two-dimensional ultrasound were used to measure the diameter, area & 
perivalvular leakage of the valved stent, as well as to assess the valve 
function and fixation of valved stent. 
Pressure of the left atrium and ventricle (proximal and distal to the 
valved stent) was measured by puncturing them with a needle. 
The animals were all sacrificed in order for as to check the adequate 
position of the valved stents. 
4.2.5 Statistical analysis 
Data was analyzed with SPSS software (Statistical Package for the 
Social Sciences). Paired t tests were used. Values were reported as mean±SD. 
Data was used from all animals who survived the entire observation period 
(n=8). 
4.3 Results: 
(1) During the experiment, the vital signs were stable & 8 pigs survived 
the manipulation (Tab 5). The mean survival time was 97 .5±56.3 minutes 
( 40-180 minutes, we killed the pig if it survived longer than 180 
minutes)(Tab 6). 
(2) Intra-vascular ultrasound showed complete opening and closure of 
the valve (Fig 17, video 6 in CD-rom). The mean diameter of mitral valve 
was 24.9±0.6 mm and the area was 421.4±17.5 mm2 before implantation. 
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Comparatively, they were 19.8±0.4mm and 238.5±15.2mm2 respectively 
after implantation (Tab 7). 
Fig 17 Intra-vascular ultrasound showed complete opening and closure of 
the valve (left: before implantation; right: after implantation) 
(3) The mean diastolic pressure gradient across the self-expanded 
stent mounted valve was 2.6±3.l rnmHg (range 0-8 rnmHg) during invasive 
measurement (Tab 8). The mean systolic pressure gradient across LVOT (left 
ventricle outlet tract) was 6.6±5.2 mmHg (range 1-15 mmHg) using the 
same procedure(Tab 9). 
( 4) Two-dimensional echocardiography and intra-cardiac ultrasound 
confirmed complete valve opening and closure of the valved stents and little 
regurgitation (Fig 18)(video 7 in CD-rom). 
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Fig 18 Two-dimensional echocardiography and intra-cardiac ultrasound 
showed a good fixation of the valved stent in the mitral position 
(5) Postmortem evaluation also confirmed a good fixation of the 
valved stents in mitral position. There was no significant obstn1ction in the 
left ventricle outflow tract (Fig 19). 
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Valved stent in 
mitral position 
Fig 19 Postmortem evaluation confirmed a good fixation of the valved 
stents in the mitral position and no left ventricle outflow tract 
obstruction . 
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4.4 Discussion 
Since Davies H. deployed a catheter-mounted unicuspid valve above the 
aortic valve for the relief of aortic insufficiency in 1965[6], much effort has 
been made to develop valved stent implantation. Off-bypass implantation of 
a valved stent in the pulmonary position can now be achieved[18]. Aortic 
valved stents can be successfully implanted without thoracotomy by using a 
transluminal catheter technique [9-11,14-16,55]. Furthermore, 
percutaneous insertion of pulmonary valve has also been achieved[13,56,57]. 
However, papers about valved stents focus on semilunar cardiac valves at all 
times, while few studies can be found about valved stents in the mitral 
position. 
Although we were aware of the difficulties that we might encounter, 
experiences from our previous off-pump pulmonary and aortic valved stent 
implantation encouraged us to attempt implantation in the mitral valve 
position[l 7-19], which has special anatomical significance. We designed a 
type of self-expanding valved stent specially intended for an 
atrio-ventricular valve. This valved stent is ") (" shape, lilœ double opposite 
crowns, & secure fixation in mitral position was easily accomplished. We 
thought of aortic or pulmonary homografts for mitral valves from the 
Ross II procedure[ 44,58,59]. These special designs made it possible to 
implant valved stents in the mitral position. 
This article presents the first description and preliminary results of a 
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new self-expandable artificial heart valve designed for implantation in the 
mitral position without extracorporeal bypass. 
Valved stents design and deployment: 
Because of the special anatomy of atrio-ventricular valve, the valved 
stent was made up of two systems, a valve system and a fixation system. We 
chose porcine aortic or pulmonary valves (homograft), as they were easily 
obtainable and mounted them into a Dacron prosthetic tube graft, which was 
used to support the homograft. Two self-expandable nitinol Z-stents were 
constructed with ") (" shape, like double opposite crowns, and secure 
fixation in the mitral position was easily accomplished. The two systems 
were connected only in the center of the device to avoid mutual interference. 
The valved stents had a profile of 1 Omm after hand compressing. 
Fortunately, we deployed the valved stents via the left atrium, thus there 
were few limitations for the size of the delivery introducer system. The 
introducer was eut to 25 to 30 cm in length for easy manipulation, and its tip 
was kept short ( <2cm ), because there was not enough space in left ventricle. 
The valved stents were unloaded from the introducer system in a staged 
procedure. The ventricular stent was deployed first, when we could still 
adjust the position and direction of the valved stents, after which the atrial 
stent was deployed. This approach increased the successful rate of 
deployments. 
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Feasibility of implantation: 
The most important goal of our study was to evaluate the feasibility of 
the off-pump implantation of the self-made valved stent in the mitral 
position. In our short-term experiment, the duration of deployment was 
about 15-20 seconds, so hemodynamic stability could be expected. Via 
pretest studies in 2 pigs, we successfully implanted the valved stents in the 
mitral position in 8 pigs with the aforementioned method. The implanted 
valved stents functioned well, and there were no significant changes in ECG, 
HR, BP, CO, PAP readings before versus after implantation for the duration 
of the experiments (survival time 40-180 minutes). Two-dimensional 
echocardiography and intra-vascular ultrasound showed complete valve 
opening & closure. Postmortem evaluation confirmed the good positioning 
of the valved stents in the mitral position. 
Possible clinicat implications: 
This preliminary study showed the feasibility of an off-pump 
implantation of the valved stent in the mitral position, which can be used as 
part of the treatment of patients with mitral regurgitation who are not 
candidates for open heart surgery, such as those with severe heart failure as 
well as hepatic and renal function failure. Implantation of valved stents 
may protect the left ventricular function from severe regurgitation, even 
temporarily. The morbidity of reoperation might decrease after alleviation of 
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left heart dysfunction by implantation of valved stent. 
Problems: 
Because the native mitral leaflets were not removed in this study, le:ft 
ventricle outflow tract (LYOT) obstnlCtion might have occurred due to a 
compressed anterior leaflet. Maybe this was one of reasons that the pigs 
couldn't survive longer. However, it must be underlined we used a healthy 
heart in our experiment. Nevertheless, the large size of left ventricle in the 
patients with severe mitral regurgitation should reduce LYOT obstn1ction. 
Furthermore, we could incise the anterior leaflet by robotic surgery m 
working heart before implantation if necessary[ 60]. 
Although we decided on the size of valved stent according to the size of 
mitral annulus measured by ultrasonography, a mismatch between the valved 
stent and annulus was observed in case 2, where paravalvular leakage and 
dislodgement of the stent occurred inevitably. Maybe this was also one of 
reasons that the pigs couldn't survive longer. Two pigs in our experiment 
survived only forty minutes after implantation. 
Because only an acute study was performed, the long-term durability 
and stability of the valved stents are unknown. 
However, up until now, all catheter-delivered valved stents had been 
intended for temporary, not long-term placement and use. Our experiment 
also focused on short-term testing at present . 
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4.5 Conclusion: 
The in vivo acute experiments confirmed the feasibility of an off-pump 
implantation of the self-expanding valved stent in mitral position, but 
long-term performance must still be established. 
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Appendices I 
Valved Homograft 
Dacron Z stent 
stents Diameter Height Diameter Height Diameter Height (mm) (mm) (mm) (mm) (mm) (mm) 
1 19.9 9.1 23 15.5 30.0 15.0 
2 22.2 9.9 25 16.6 30.0 15.0 
3 20.1 10.5 23 15.1 30.0 15.0 
4 20.4. 9.9 25 15.4 30:0 15.0 
5 19.7 9.5 23 14.5 3_0.0 15.0 
Mean 20.46 9.78 23.80 15.42 30.0 15.0 
SD 1.01 0.52 t09 0.77 0 0 
Tab lThe dianiefer ahd height of each part ofthe valved stents. 
Val ved stent Height Inner diaineter (mm) Oùter diarileter (mm) (mm) 
1 29.1. 19.9 24.5· 
2 29.6 22.2 -26.3 
3 29.4 20.1 24.8 
4 29.4 ·. 20.4 25,9 
5 22.2 19.7 24.5 
Mean 29.34 20.46 25.20 
SD 0.19' 1.00 0.84 
Tab 2. The meà.sured sîzes of the coristructed valved stents 
Leakage Valved stents 
(ml/min) 1 2 3 4 5 mean±SD 
1 68.2 29.6 46.5 31.5 40.4 43.2±15.5 
2 53.4 33.4 55.2 41.l 28.8 42.4±11.8 
,.., 37.5 42.8 39.2 58.6 34.4 42.5±9.5 .) 
4 30.8 54.7 36.8 42.1 35.6 40.0±9.1 
5 45.4 47.6 30.9 34.3 39.8 39:6±7.1 
mean±SD 47.1±14.5 41.2±10.2 41.7±9.4 41.6±10.6 35.-8±4.7 41.5±10. l 
Tab 3 The leakage test un der a 80cmH20( 60mmHg)-water column pressure 
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•.•. œt<' 
N Weight(kg) Age(weeks) sex . HR(bpm) BP(mmHg) CVP(mmBg) ECG 
16 56 10 M 93 95/53 1 NSR 
17 44 8 M 103 102/67 5 NSR 
18 45 8 F 83 80/44 4 NSR 
24 48 8 M 90 85/60 3 NSR 
25 44 7 F 85 84/52 7 NS-R 
26 44 6 F 83 95/60 5 ·NsR 
27 44 6 F 95 110/60 3 NSR 
28 43 6 M 103 88/52 4 NSR 
Mean 46.0 7.3 91..9 92.4/56:0 4.0 
SD 4.3 L4 8.2· 10.1/7.1 1.8: 
Taq 4. Pigs' data(NSR: Normal sinus thythm) 
Befote implantation After împlantation T value 
HR 96.71:±:7.98 93:29±13.29 0.307 (no sig) 
SBP 91.88±3.48 83.43±4.28 2.382 (no sig) 
DBP 53.14±4.54 49.57±10.18 0.563 (no sig) 
PAP 16.57±5.22 16.8.5±2,97 0.162 (no sig) 
WPAP 3.86±0.89 4.14±0.69 0.603 (no sig) 
CO 5.78±0.31 5.60±0.54 0.594 (no sig) 
CVP 2.00±1.29 2.57±0.53 1.922 (no.sig) 
Ta_b 5 Vital signs before and a:fter implantation (mean±SD) and ttest. (t<3.055,p>0.005, 
no significance) 
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Number Survival time(minutes) Possible cause ofdeath 
16 180 Killed by experimenter 
17 80 Dislodgement ofvalved stent 
18 60 Arrhythmia, [K+]7.2mmol/l 
24 180 Killed by experimenter 
25 50 LVOT obstruction 
26 120 Dislôdgement of valved stent 
27 40 ArrJiythmia, [K+]8. lmmol/l 
28 70 Undefined 
Meàn 97.5 
SD 56.3 
tab 6 The pigs' survival time and theirpo"ssibte Çauseof death 
Before implantation . After implantation 
N MV diameter(cm) MV area(èfu2) MV diameter(c!rl) MV area( cm2) 
16 25.6 440.53 20.2 256.40 
17 24.8 427.46 19.8, 220.58 
18 24.5 20.0 
24 24.9 418.87 19.5 243.77 
25 25.9 19.8 
26 24.5 20.4 
27 24.8 398.73 19.5 233.44 
28 23.9 19.4 
Mean 24.9 421.4 19.8 238.5 
SD 0.6 17.5 0.4 15.2 
Tab 7 Mitral valve diameter. and area before and after implantation. 
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N 
24 
25 
26 
27 
28 
Mean 
SD 
N 
24 
25 
26 
27 
28 
.Mean 
.SD 
LA pressure(mmHg) LV pressure(inmHg) Diastolic gradient(mmHg) 
14 75/12 2 
22 100/20 2 
18 89/10 8 
9 85/8 1 
7 71/8 0 
14.0 8_4.0/Ll .6 2.6 
6.2 11.5/4.9 3.1 
· Tab 8 The pressure gradiEmt aoross the mitral valved stent 
measured after the needle puncture. 
LV press'Ure(rhmHg) AO preqs.ure(mmHg) Systolic gradient(mmHg) 
75/12 70/40 5 
100/20 85/48 15 
89/10 82/50 7 
85/8 80/45 5 
71/8 70/40 1 
84.0/11.6 77..4/44.6. 6.6 
11.5/4.9 6.9/4.5 5.2 
Tab 9 The pressure gradient across the LYOT measured:after the needle puncture. 
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Appendices Il 
Videô 1. M~itral valve anatomy 
Video 2_. Valved stent delivery process in vitro 
Video 3.. Mock loop testing prooess 
Vide ci 4. IVU~rshérvv valve& stept'ip_ m_ock loop test 
Video 5. - Endoscfopic- view.6f va)v$d stent'in: rfiock.loop _tèst 
Vicleo·6. ' rvus_\fÎ~cl~o dfV-alyecl'gtentinvivo·tySL 
· Video 7. ICUS-video ofvalved stent in-vivo -tesl 
. . . . . ' . . . ' . -
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